(Adnkronos) - “L’elacestrant è una molecola che arriverà nelle nostre farmacie. Il vantaggio di questa terapia endocrina è che allontana, dalle pazienti affette da carcinoma mammario, la chemioterapia. Per adesso in Italia abbiamo un solo accesso con richiesta, ma la novità importante è che questa mutazione si può valutare con una biopsia liquida”. Lo ha detto Saverio Cinieri, presidente della Fondazione Aiom, Associazione italiana oncologia medica, a margine di un corso di aggiornamento tenutosi a Roma sul carcinoma mammario Er+/Her2 - avanzato o metastatico con mutazioni Esr1.
Category
🗞
NewsTranscript
00:00What are the benefits of L-Helicestat?
00:04L-Helicestat is a new molecule,
00:06which is the first class of molecules
00:09that will arrive in our pharmacies.
00:14The concept of L-Helicestat already exists
00:17and is dedicated to patients
00:19who have a mutation called ESR1.
00:22The advantage for patients is that
00:24they avoid another step,
00:26that is, they move away from chemotherapy,
00:29because this endocrine therapy
00:31can now be administered in women
00:33who have escaped endocrine therapy in the first place.
00:36It is a bit that changes the global approach
00:38to patients with positive hormone receptors,
00:40because the time of chemotherapy,
00:42which rightly scares our patients,
00:44moves away from months, many months,
00:47from the beginning of the metastasis,
00:49and it is certainly a step forward.
00:51We have an expanded access,
00:53at the moment in Italy it means
00:55an access with request,
00:57of the ESR1 mutation,
00:59which is present in 30% of 70% of women
01:02with endocrine-responsive breast cancer.
01:05The important novelty is that
01:08this mutation can be evaluated
01:11on a blood test, the so-called liquid biopsy.
01:14So the liquid biopsy also enters
01:16in breast cancer, as it has already entered
01:18in other pathologies, as an important thing,
01:21a target, a blood sample,
01:23and it says if you are mutated,
01:25you have the possibility of accessing the drug.
01:27I was saying in expanded access,
01:29but there are many experiments in progress
01:31in our country, I remember that the molecule
01:33is produced by an Italian company,
01:35and I say this with pride, because Italy
01:37is facing the pharmaceutical market again,
01:41after years in which we had been colonies
01:45of other countries of the world,
01:47of multinational and non-Italian,
01:49I was saying, we have many studies,
01:51we will soon have the availability,
01:53of the molecule.
01:54Well, keep in mind that in the past,
01:56if we had to do a study of a further mutation
01:58to the disease profession,
02:00we had to take a piece of tissue,
02:02so a hepatic biopsy, an osteoporosis biopsy,
02:04a pulmonary biopsy, often meant
02:06surgical interventions, pain,
02:08and waiting.
02:10Now, a blood test, which is
02:13elaborated from a technical point of view,
02:16even in a few days,
02:18allows us to say, through a blood sample,
02:20if there is or is not this mutation,
02:22if we can access this new molecule.